Lifecare – Valuation Report of the Sencell technology (CGM) for diabetes
This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intends", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. The Company does not accept any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise, other than as may be required by law.
Bergen, Norway, November 1st, 2023: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes a new valuation report of Lifecare’s CGM-technology.
The report is enclosed and available on the Company's website lifecare.no/news/
Commissioned by Lifecare, the life science technology valuation-company Xplico has carried out an in-depth value review of the Sencell technology. For the evaluation, Xplico has obtained information from Lifecare, but in their disclaimer they also emphasized how they have evaluated the information provided to them through broad inquiry, analysis and review.
In this valuation of Lifecare's technology, Xplico has taken into consideration various factors like development and market assumptions, comparable CGM technologies and concluded a valuation outcome.
- The valuation is comprehensive and provides an assessment of net present values of Lifecares technology. The evaluation also provides, among other things, assessments regarding the probability of success in the markets we have targeted. In addition, the report shows market share and anticipated annual treatment price at launch. For the very first time, the spin-off venture towards the veterinary market has also received a separate review. The valuations of the technology in the markets for both humans and pets confirm the possibilities of Lifecare's technology, announces CEO Joacim Holter at Lifecare.
Xplico is a market leader in life science valuation. Half of their client base is in North America, while the rest of the assignments come from customers in Europe and Asia. Annually, Xplico carries out a broad range of company valuations in addition to offering standardized valuation tools.
